pEYS606

Biologic

EEyevensys

pEYS606 is one of 6 biologic programs targeting Panuveitis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PanuveitisActive, not recruiting

PanuveitisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Panuveitis

#DrugCompanyPhaseTrials

Lupkynis

Aurinia Pharmaceuticals

LFG316

1 3

Actemra

Roche

Phase 1

—4

Synalar

EEurofarma Laboratorios S.A.

Phase 1

1 5

Humira

pEYS606

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Panuveitis1 trial

Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis

Completed·EEyevensys·Phase 1/2·NCT03308045·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for pEYS606. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pEYS606 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pEYS606. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eyevensys company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: EEyevensys

pEYS606

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Panuveitis1 trial

References

Drug Info

Quick Facts

Related News